Sensible police reform includes changing ‘qualified immunity’ laws

Share on Facebook
Share on Twitter
Share on
LinkedIn
+

This op-ed originally appeared in WGBH News, The Lowell Sun, The Fitchburg Sentinel & Gazette, Salem News, and the Gloucester Daily Times.

By Jim Stergios and Charlie Chieppo

Even in a time of painful divisions in our country, there is little doubt among people of good faith that what Derek Chauvin and three other former Minneapolis police officers did to George Floyd was criminal. If they are indeed convicted of a felony, how is it that the former officers could very well be immune from civil liability?

The answer lies in Harlow vs. Fitzgerald, a 1982 U.S. Supreme Court case. There, the justices ruled that public officials should have “qualified immunity.” In practice, qualified immunity nearly exempts public officials from civil liability for their actions, no matter how egregious. The Court found that officials can only be found liable if they violate “clearly established law.” As applied to the Floyd case, it means that unless there is a federal case finding that kneeling on a person’s neck until the person dies is illegal, Chauvin wouldn’t incur civil liability.

If you think that couldn’t possibly be true, consider the Sixth Circuit Court of Appeals’ 2019 decision in Baxter vs. Bracey. A panel of judges found that two police officers who unleashed a dog on a suspect who was sitting down with his hands up were entitled to qualified immunity because, even though an earlier ruling found that officers were not allowed to sic a dog on someone who was lying down, no case ever addressed whether the same was true for a suspect who was sitting with his hands up.

For Americans to have faith in our legal system, the system must be rational, and providing felons with immunity from civil liability doesn’t pass the smell test. Nor does the idea that public officials can violate our rights with impunity as long as they come up with a way to do it that no federal court has yet addressed.

In the wake of Floyd being killed, a bill introduced by Rep. Justin Amash of Michigan would bring us closer to the ideals outlined in the Constitution. Massachusetts Rep. Ayanna Pressley is among more than 50 co-sponsors of the “Ending Qualified Immunity Act.”

The need for such legislation was highlighted just this month, when the Supreme Court refused to hear several cases that challenge qualified immunity, including Baxter vs. Bracey.

Freedom from bad faith violations of our constitutional rights by those sworn to uphold them is among the most basic things we expect from government. We cannot have a healthy republic if public officials don’t respect our rights, and subjecting public officials who trample individual liberties to civil liability is the surest way to protect those rights.

Ending qualified immunity from civil liability would help restore faith in our system, ensure respect for constitutional rights and provide a fair remedy to George Floyd, his family and other victims of bad faith violations. Let’s use this moment of near unanimity about the horror of what was done to Floyd to prevent others from having their rights trampled by the very people we rely on to protect them.

Get Our COVID-19 News, Tips & Resources!

Browse our recent commentary:

Removal of Mass. and Cass encampment long overdue

Michelle Wu’s plan to clear tents from the Mass. and Cass homeless camping site by January 12 is long overdue. If only it had been done earlier, the move could have averted a humanitarian crisis.

Maine Tries to Ignore a Clear Supreme Court Ruling on Education

As the U.S. Supreme Court takes up Carson v. Makin, the facts are clear. Maine has chosen to subsidize private education. As such, it cannot disqualify all religious schools from receiving public dollars under its school choice program.

Time for State Action on Troubled Boston Schools

Given the failures of both appointed and elected school boards, perhaps the time has come to have the state Department of Elementary and Secondary Education appoint the members of the Boston School Committee. Patience might be warranted if the Boston Public Schools were improving. But we have waited for decades, and they are only getting worse. Holding adults in the system accountable was a cornerstone of the Education Reform Act. If not now, when?

A Modest Proposal to Raise Federal Revenue

As a way to tackle drug prices, President Joe Biden recently announced that he supports the so-called “inflation rebate,” which would require drug companies to give the federal government any revenue from Medicare drug prices above the general rate of inflation. Senate Finance Committee Chairman Ron Wyden and House Speaker Nancy Pelosi have also publicly endorsed the inflation rebate.

Why are health care costs rising every year in Massachusetts?

/
The largest driver is the increase in prices by health systems that have the clout to command higher payments and work to recruit more patients to their high-cost facilities.

A truly progressive student loan policy

/
This op-ed originally appeared in the Boston Globe. It was written…

A Rare Victory for Transparency. Massachusetts Could Use Many More.

/
Massachusetts is in the midst of wrongdoing on an unprecedented scale. Thousands of convictions had to be vacated because of the corruption of state drug laboratory chemists. Thousands more convictions were vacated because of the combined misconduct of the chemists and prosecutors. And still more will be vacated because of the Commonwealth’s repeated and deliberate failures to investigate the extent to which its evidence was compromised.

A Rush to Judgment on Alzheimer’s Drug

/
The Boston-based Institute for Clinical and Economic Review (ICER) sells itself as an independent source of information on the value of pharmaceuticals. But earlier this month, their bias was again evident when they tried to kneecap a drug for a dreaded disease before there’s even enough data to determine how valuable the drug really is. ICER has adopted this same strategy in the past on innovative drugs for cancer, cystic fibrosis, and other devastating diseases. This time ICER’s target is aducanumab, Biogen’s drug for Alzheimer’s disease.